2型糖尿病の予防のためのアカルボス: STOP-NIDDMランダム化試験
Jean-Louis Chiasson1, Robert G Josse, Ramon Gomis
1Research Centre, Centre Hospitalier de l'Université de Montréal, Hôtel-Dieu, Department of Medicine, University of Montreal, Quebec, Canada. jean.louis-chiasson@umontreal.ca
Lancet (London, England)
|June 28, 2002
まとめ
アカルボスは,グルコース耐性障害の患者で2型糖尿病の発症を著しく遅らせました. このアルファ-グルコシダース阻害剤は,また,正常なグルコース耐性への回復を促進し,新しい治療選択肢を提供しました.
科学分野:
- エンドクリノロジー エンドクリノロジー
- メタボリック疾患
- 薬理学 薬理学とは
背景:
- 2型糖尿病 (T2DM) は,世界的な健康上の懸念が高まっています.
- 血糖耐性障害 (IGT) はT2DMの前駆体である.
研究 の 目的:
- アカルボースが,IGTからT2DMへの進行を予防または遅らせる効果を評価する.
主な方法:
- IGT患者を含む多センター,ランダム化,プラセボ対照試験です.
- 参加者は,アカルボース100mgまたはプラセボを1日3回投与された.
- 主なアウトカムは,毎年口服によるグルコース耐性検査 (OGTT) により評価された糖尿病の発症でした.
主要な成果:
- アカルボースは,IGTからT2DMへの変換を著しく低下させました (相対的な危険度0.75; p=0.0015).
- アカルボースの治療は,IGTが正常なグルコース耐性 (p<0.0001) に戻るのに有意な増加をもたらしました.
- アカルボースの一般的な副作用には,浮気や下痢が含まれていました.
結論:
- アカルボースは,IGTを有する個体においてT2DMの発症を遅らせるのに有効です.
- 糖尿病予防のためのライフスタイル変更の代替または補助として使用することができます.
- アカルボースは,前糖尿病の管理のための潜在的な治療戦略を提供します.
関連する概念動画
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...